Castle Biosciences (CSTL) Cash & Current Investments (2018 - 2026)

Castle Biosciences has reported Cash & Current Investments for 9 years, with the latest figure at $266.8 million in Q2 2026.

• Quarterly Cash & Current Investments fell 3.3% year-over-year to $266.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $266.8 million (down 3.3% YoY) and the FY2025 annual result came in at $299.5 million, up 2.17% from the prior year.
• Cash & Current Investments climbed to $266.8 million in Q2 2026 per CSTL's latest filing, from $261.7 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $309.0 million in Q1 2022 and troughed at $225.5 million in Q2 2023.
• A 5-year average of $265.3 million and a median of $266.4 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments retreated 26.76% in 2022, then increased 21.79% in 2024.
• Over 5 years, Cash & Current Investments stood at $258.6 million in 2022, then decreased by 6.0% to $243.1 million in 2023, then climbed by 20.58% to $293.1 million in 2024, then gained by 2.17% to $299.5 million in 2025, then slipped by 10.91% to $266.8 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $266.8 million, $261.7 million, and $299.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.